KRAS and lung carcinoma: The first evidence that inhibition of oncogenic KRAS is beneficial from a therapeutic viewpoint came from immunocompetent genetically engineered mouse models (GEMMs) of lung cancer in which lung tumors completely regressed upon genetic removal of mutant KRAS [24,25,26].